PBU The Pension Fund of Early Childhood & Youth Educators Makes New $10.09 Million Investment in Medtronic PLC $MDT

Key Points

• PBU The Pension Fund of Early Childhood & Youth Educators opened a new position in Medtronic, buying 105,030 shares worth about $10.09 million in the fourth quarter.
• Medtronic reported better-than-expected quarterly results, with earnings of $1.55 per share and revenue of $9.81 billion, both ahead of consensus estimates. The company also reiterated FY2027 EPS guidance of 5.90 to 6.00.
• Medtronic raised its quarterly dividend to $0.72 per share, up from $0.71, implying an annualized dividend of $2.88 and a yield of about 3.5%.

PBU The Pension Fund of Early Childhood & Youth Educators bought a new position in Medtronic PLC (NYSE:MDT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 105,030 shares of the medical technology company's stock, valued at approximately $10,089,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Lodestone Wealth Management LLC bought a new position in Medtronic during the 4th quarter worth approximately $27,000. Anfield Capital Management LLC grew its position in Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company's stock worth $27,000 after acquiring an additional 230 shares during the last quarter. Board of the Pension Protection Fund bought a new position in Medtronic during the 4th quarter worth approximately $29,000. GoalVest Advisory LLC bought a new position in Medtronic during the 4th quarter worth approximately $29,000. Finally, Imprint Wealth LLC bought a new position in Medtronic during the 3rd quarter worth approximately $31,000. Hedge funds and other institutional investors own 82.06% of the company's stock.

Medtronic Trading Down 0.3%

NYSE MDT opened at $81.66 on Friday. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The stock has a 50 day simple moving average of $81.46 and a two-hundred day simple moving average of $92.04. The stock has a market cap of $104.84 billion, a P/E ratio of 21.89, a price-to-earnings-growth ratio of 1.99 and a beta of 0.58.

Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.01. Medtronic had a return on equity of 14.61% and a net margin of 13.20%.The business had revenue of $9.81 billion during the quarter, compared to analysts' expectations of $9.62 billion. During the same quarter last year, the business posted $1.62 EPS. The business's revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, analysts forecast that Medtronic PLC will post 5.94 earnings per share for the current year.

Medtronic Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 17th. Stockholders of record on Friday, June 26th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.5%. The ex-dividend date is Friday, June 26th. This is a boost from Medtronic's previous quarterly dividend of $0.71. Medtronic's dividend payout ratio (DPR) is 76.14%.

Analyst Ratings Changes

Several research firms recently issued reports on MDT. Daiwa Securities Group reduced their price target on Medtronic from $117.00 to $115.00 and set a "buy" rating on the stock in a research report on Friday, February 27th. Sanford C. Bernstein reduced their price target on Medtronic from $112.00 to $97.00 and set an "outperform" rating on the stock in a research report on Thursday. Argus reduced their price target on Medtronic from $125.00 to $115.00 and set a "buy" rating on the stock in a research report on Monday, April 6th. JPMorgan Chase & Co. reduced their price target on Medtronic from $100.00 to $86.00 and set a "neutral" rating on the stock in a research report on Thursday. Finally, The Goldman Sachs Group reduced their price target on Medtronic from $84.00 to $83.00 and set a "neutral" rating on the stock in a research report on Thursday. Seventeen equities research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to data from MarketBeat, Medtronic currently has a consensus rating of "Moderate Buy" and an average target price of $99.00.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s fiscal Q4 results beat revenue expectations and showed continued year-over-year growth, while management signaled confidence in the company’s FY26/FY27 growth outlook and new product platforms. Medtronic (MDT) Climbs 5.7% on Stellar Q4
• Positive Sentiment: BTIG upgraded Medtronic to Buy with a $90 target, citing a strong revenue beat and improving organic growth, while other firms such as TD Cowen and RBC reaffirmed bullish ratings. Wall Street May Be Mispricing Medtronic, Analyst Says
• Positive Sentiment: Medtronic expanded its relationship with Retia Medical to distribute the Argos Cardiac Output Monitor across Western Europe, adding to its cardiovascular portfolio and international reach. Retia Medical Expands Distribution of Argos® Cardiac Output Monitor to Western Europe with Medtronic
• Positive Sentiment: Medtronic also announced a higher quarterly dividend, signaling confidence in cash generation and shareholder returns. Medtronic (MDT) Climbs 5.7% on Stellar Q4
• Neutral Sentiment: Several brokerages lowered price targets after earnings, but most still kept Buy/Outperform or Hold/Neutral ratings, suggesting a reset in expectations rather than a major change in long-term views. Rothschild & Co Redburn cuts Medtronic price target
• Neutral Sentiment: Analyst roundups highlighted that Wall Street’s average recommendation remains Buy, but those consensus ratings are often viewed as overly optimistic and not always predictive. Is Medtronic (MDT) a Buy as Wall Street Analysts Look Optimistic?
• Negative Sentiment: Medtronic is still dealing with ongoing cardiovascular device recalls tied to potential sterile barrier issues, which could weigh on investor sentiment and create some execution risk. Medtronic Balances Hugo Robotics Expansion With Ongoing Cardiovascular Device Recalls

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.